Roche expands hepatitis diagnostics portfolio
Almost 300 million people globally have chronic hepatitis B
Almost 300 million people globally have chronic hepatitis B
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Decision on EU marketing authorisation expected for momelotinib by early 2024
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Subscribe To Our Newsletter & Stay Updated